Home > Boards > US Listed > Medical - Healthcare > Mylan Inc. (MYL)

Mylan Drops After FDA Finds Deficiencies In Its

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
ITMS Member Profile
Member Level 
Followed By 42
Posts 1,447
Boards Moderated 1
Alias Born 10/13/09
160x600 placeholder
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 7/10/2019 1:09:35 PM
Novartis to Supply EpiPen Alternate to U.S. Pharmacies -Reuters Dow Jones News - 7/9/2019 7:30:00 PM
Mylan and Atomo Diagnostics Announce WHO Prequalification Approval for Mylan HIV Self Test PR Newswire (US) - 7/8/2019 12:42:00 PM
Medexus Appoints Accomplished Global Pharmaceutical Industry Executive Adele M. Gulfo to its Board of Directors GlobeNewswire Inc. - 6/25/2019 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/21/2019 5:02:33 PM
Theravance Biopharma and Mylan Expand YUPELRI® (revefenacin) Development and Commercialization Agreement to Include China an... PR Newswire (US) - 6/14/2019 8:05:00 AM
Theravance Biopharma and Mylan Expand YUPELRI® (revefenacin) Development and Commercialization Agreement to Include China an... PR Newswire (US) - 6/14/2019 8:05:00 AM
Notice of Exempt Solicitation Pursuant to Rule 14a6(g) (px14a6n) Edgar (US Regulatory) - 6/13/2019 12:59:29 PM
Notice of Exempt Solicitation Pursuant to Rule 14a6(g) (px14a6n) Edgar (US Regulatory) - 6/7/2019 1:30:36 PM
Notice of Exempt Solicitation Pursuant to Rule 14a6(g) (px14a6n) Edgar (US Regulatory) - 5/31/2019 7:14:02 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 5/24/2019 5:13:35 PM
Theravance Biopharma and Mylan Present Additional YUPELRI® (revefenacin) Phase 3 Data Analysis at the 2019 ATS International... PR Newswire (US) - 5/20/2019 10:15:00 AM
Theravance Biopharma and Mylan Present Additional YUPELRI® (revefenacin) Phase 3 Data Analysis at the 2019 ATS International... PR Newswire (US) - 5/20/2019 10:15:00 AM
Mylan Presents Equivalence and Device Usability Data on Wixela™ Inhub™ Compared to Advair Diskus® at American Thoracic S... PR Newswire (US) - 5/18/2019 10:45:00 AM
Mylan to Host Investor Day on July 31, 2019 in New York City PR Newswire (US) - 5/17/2019 8:00:00 AM
Mylan and Biocon to Present Final Overall Survival Data for Ogivri™ (trastuzumab-dkst), a biosimilar to Herceptin®, at the... PR Newswire (US) - 5/15/2019 5:01:00 PM
Mylan Expands Oncology Portfolio with Launch of Generic Tarceva® Tablets PR Newswire (US) - 5/10/2019 9:45:00 AM
Mylan to Present at the 2019 Bank of America Merrill Lynch Healthcare Conference PR Newswire (US) - 5/10/2019 8:00:00 AM
Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) Edgar (US Regulatory) - 5/10/2019 6:08:13 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/7/2019 11:07:10 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/7/2019 8:37:17 AM
Mylan Reports First Quarter 2019 Results and Reaffirms 2019 Guidance PR Newswire (US) - 5/7/2019 8:30:00 AM
Amended Annual Report (10-k/a) Edgar (US Regulatory) - 4/30/2019 4:44:34 PM
Mylan to Release First Quarter 2019 Financial Results on May 7, 2019 PR Newswire (US) - 4/26/2019 7:30:00 AM
TB Alliance and Mylan Announce Global Collaboration to Commercialize Investigational Drug Pretomanid as Part of Two Regimens ... PR Newswire (US) - 4/18/2019 8:00:00 AM
ITMS Member Level  Thursday, 06/14/18 12:26:45 PM
Re: None
Post # of 141 
Mylan Drops After FDA Finds Deficiencies In Its Version of Advair, Watch This Level

Shares of the pharmaceutical giant, Mylan NV (NASDAQ:MYL), are falling by nearly 5.0 percent to $39.70 a share. The sharp decline in the stock comes after the FDA said that it found minor deficiencies in Mylan's generic version of Advair. Today, the stock is fighting to stay above its important 50 and 200-day moving averages. A close below these key support levels will signal further downside in the stock price. Either way, should the stock decline further from current levels the next major support area would be around the $35.00 area. This is where the stock broke out on early May 2018 and should be defended by the institutional crowd if retested.





Nicholas Santiago
InTheMoneyStocks

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist